Page last updated: 2024-09-05

lasofoxifene and Osteoporosis, Postmenopausal

lasofoxifene has been researched along with Osteoporosis, Postmenopausal in 29 studies

Research

Studies (29)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (31.03)	29.6817
2010's	20 (68.97)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Pinkerton, JV; Thomas, S	1
Andersson, A; Bernardi, AI; Carlsten, H; Islander, U; Nurkkala-Karlsson, M; Ohlsson, C; Stubelius, A	1
Gennari, L	3
Eastell, R; Glover, SJ; Rogers, A	1
Lewiecki, EM	1
Gennari, L; Merlotti, D; Nuti, R	1
Armstrong, RA; Cummings, SR; Delmas, PD; Eastell, R; Ensrud, K; Goldstein, S; Kendler, D; LaCroix, AZ; Lee, A; Neven, P; Powles, T; Reid, DM; Sriram, U; Thompson, DD; Thompson, J; Vukicevic, S; Zanchetta, J	1
Becker, C	1
Malozowski, S	1
Katzeff, BS	1
Andreu, JL; Silva-Fernández, L	1
Colgan, T; Cummings, S; Goldstein, SR; Johnson, M; Krpan, D; Neven, P; Proulx, J; Runowicz, CD; Sriram, U; Thompson, D; Thompson, J	1
Armstrong, R; Barrett-Connor, E; Cauley, J; Cummings, S; Eastell, R; Ensrud, K; LaCroix, A; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Welty, F	1
Allred, DC; Armstrong, R; Cummings, SR; Curto, M; Eastell, R; Ensrud, KE; Goss, P; LaCroix, AZ; Lee, A; Neven, P; Osborne, CK; Powles, T; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Wolter, K	1
Vogel, VG	1
Schmidt, C	1
Hamilton, CJ; Jamal, SA; Swan, VJ	1
Archer, DF	1
Gennari, L; Naunton, M; Peterson, GM; Tichelaar, LK	1
Chines, AA; Komm, BS	1
Cummings, SR; Eastell, R; Ensrud, KE; LaCroix, AZ; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S	1
Hadji, P	1
Calaf Alsina, J; Coronado Martín, PJ	1
Ke, HZ; Maeda, T; Simmons, H; Thompson, D	1
Goldstein, SR	1
Ohta, H	1

Reviews

14 review(s) available for lasofoxifene and Osteoporosis, Postmenopausal

Article	Year
Use of SERMs for treatment in postmenopausal women. The Journal of steroid biochemistry and molecular biology, 2014, Volume: 142 Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene	2014
Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:13 Topics: Atrophy; Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vagina; Vaginal Diseases	2009
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. Journal of women's health (2002), 2009, Volume: 18, Issue:10 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health	2009
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clinical interventions in aging, 2010, Feb-02, Volume: 5 Topics: Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes	2010
Lasofoxifene in osteoporosis and its place in therapy. Advances in therapy, 2010, Volume: 27, Issue:12 Topics: Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Female; Humans; Middle Aged; Musculoskeletal Diseases; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Women's Health	2010
Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:4 Topics: Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; United States; United States Food and Drug Administration	2011
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas, 2012, Volume: 71, Issue:3 Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes	2012
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action]. Medicina clinica, 2013, Mar-16, Volume: 140, Issue:6 Topics: Adenocarcinoma; Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Multicenter Studies as Topic; Organ Specificity; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Thromboembolism	2013
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Animals; Bone Density; Breast Neoplasms; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Mice; Osteoporosis, Postmenopausal; Pyrrolidines; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Transcription, Genetic; Uterus	2004
Lasofoxifene (Pfizer). Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:10 Topics: Animals; Bone Density; Clinical Trials as Topic; Drug Industry; Estrogen Receptor Modulators; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Tetrahydronaphthalenes; Treatment Outcome	2005
Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:6 Topics: Animals; Female; Humans; In Vitro Techniques; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes	2006
Not all selective estrogen response modulators are created equal: update on lasofoxifene. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2 Topics: Animals; Bone Density; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes	2006
[Status of novel bone-targeting SERMs in development]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Animals; Bone and Bones; Bone Density; Clinical Trials as Topic; Drug Design; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Receptors, Estrogen; Research; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes	2007

Trials

6 trial(s) available for lasofoxifene and Osteoporosis, Postmenopausal

Article	Year
A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone, 2009, Volume: 45, Issue:6 Topics: Adult; Biomarkers; Bone Density; Bone Remodeling; Confidence Intervals; Demography; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Pyrrolidines; Reference Values; Tetrahydronaphthalenes; Time Factors	2009
Lasofoxifene in postmenopausal women with osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Cysts; Ovarian Neoplasms; Polyps; Postmenopause; Proportional Hazards Models; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Ultrasonography; Urinary Incontinence; Uterine Diseases; Uterus	2011
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation, 2010, Oct-26, Volume: 122, Issue:17 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk Factors; Stroke; Tetrahydronaphthalenes; Treatment Outcome	2010
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Double-Blind Method; Estradiol; Female; Fractures, Bone; Humans; Incidence; Mammography; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tetrahydronaphthalenes; Treatment Outcome; United States	2010
Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone, 2012, Volume: 50, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Placebos; Pyrrolidines; Tetrahydronaphthalenes; Time Factors; Treatment Outcome	2012

Other Studies

9 other study(ies) available for lasofoxifene and Osteoporosis, Postmenopausal

Article	Year
Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:3 Topics: Animals; Area Under Curve; Arthritis, Experimental; Biomarkers; Collagen; Disease Models, Animal; Female; Flow Cytometry; Humans; Indoles; Interleukin-6; Mice; Mice, Inbred DBA; Osteoarthritis; Osteoporosis, Postmenopausal; Ovariectomy; Pyrrolidines; Random Allocation; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome	2016
Lasofoxifene: new drug. Osteoporosis: no better than raloxifene. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Europe; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes	2009
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Lasofoxifene for postmenopausal women with osteoporosis. The New England journal of medicine, 2010, Jun-10, Volume: 362, Issue:23 Topics: Bone Density Conservation Agents; Comparative Effectiveness Research; Diphosphonates; Female; Helsinki Declaration; Humans; Informed Consent; Osteoporosis, Postmenopausal; Placebos; Pyrrolidines; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes	2010
Lasofoxifene for postmenopausal women with osteoporosis. The New England journal of medicine, 2010, Jun-10, Volume: 362, Issue:23 Topics: Carcinoma, Non-Small-Cell Lung; Estrogens; Female; Humans; Lung Neoplasms; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes	2010
Lasofoxifene for postmenopausal women with osteoporosis. The New England journal of medicine, 2010, Jun-10, Volume: 362, Issue:23 Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Risk; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thromboembolism	2010
Tipping the balance for the primary prevention of breast cancer. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome	2010
Third-generation SERMs may face uphill battle. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration	2010
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:1 Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes	2011